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Abstract 
Objective: To evaluate the test performance of 47 biomarkers and ultrasound 
parameters to predict subsequent delivery of an SGA infant and adverse perinatal 
outcome in women presenting with suspected preeclampsia.  
 
Methods: In a prospective, multicentre observational study, 47 biomarkers and 
ultrasound parameters were measured in 397 women presenting with suspected 
preterm preeclampsia, with the objective of evaluating them as predictors of 
subsequent delivery of an SGA infant and adverse perinatal outcome. Factor analysis 
and stepwise logistic regression were performed in two pre-specified groups.  
 
Results: In 274 women presenting at 20+0 to 34+6 weeks’ gestation (Group 1), 96 (35%) 
delivered an SGA infant <3rd customised birthweight centile (SGA-3). For prediction of 
SGA-3, low maternal Placental Growth Factor (PlGF) concentrations had a sensitivity of 
93% (95%CI 84% to 98%) and negative predictive value (NPV) of 90% (95%CI 76% to 
97%) compared to a sensitivity of 71% (95%CI 58% to 82%) and a NPV of 79% (95%CI 
68% to 87%) for ultrasound parameters (estimated fetal weight or abdominal 
circumference <10th centile). No individual biomarker evaluated had superior 
performance to PlGF and combinations added only small increments to test 
performance. Similar results were found in 123 women presenting between 35+0 to 
36+6 weeks’ gestation (Group 2). 
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Conclusions: In women presenting with suspected preterm preeclampsia, 
measurement of PlGF offers a useful adjunct for identifying those at high risk of 
delivering an SGA infant, allowing appropriate surveillance and timely intervention. 
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Introduction 
Infants who are born small-for-gestational-age (SGA) are at increased risk of short-
term neonatal morbidity(1) and mortality(2, 3), and longer term complications 
extending into adult life, including cardiovascular disease and type 2 diabetes 
mellitus(4). SGA is commonly defined as a birthweight under a centile threshold. For 
infants under the 10th centile for the population this group includes constitutionally 
small infants and those with fetal growth restriction, the latter defined as failure of a 
fetus to reach its full growth potential. Use of birthweight centiles customised for 
additional maternal (height, weight, ethnicity, parity) and fetal (sex) variables increases 
identification of those fetuses at risk of adverse perinatal outcomes, including stillbirth 
and neonatal death(5).  
 
The underlying pathophysiology of fetal growth restriction is complex, but poor 
placentation plays a key role in a substantial proportion of SGA, particularly in women 
with preterm hypertensive disorders and when associated with adverse perinatal 
outcomes. There is a need for a test in the second half of pregnancy to identify those 
at highest risk of delivering an SGA infant. Markers of placental function could offer a 
useful adjunct to current methods of ultrasonography to improve risk stratification 
enabling identification of those at greatest risk and minimising unnecessary 
intervention for lower risk women. Several biomarkers have been suggested as 
potential predictors of fetal growth restriction, but to date, none have been shown to 
have adequate accuracy to support incorporation into clinical practice(6). Women with 
suspected hypertensive disorders of pregnancy, who present prior to 37 weeks’ 
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gestation, are at increased risk of fetal growth restriction but the optimal strategy for 
identifying such fetuses remains unclear.  
 
As part of a large prospective study in women presenting with suspected preeclampsia 
we sought first to evaluate 47 biomarkers (identified by an extensive literature search) 
and then compare the best performing biomarker(s) against currently utilised 
ultrasound parameters for determining subsequent delivery of an SGA infant and 
adverse perinatal outcome. 
 
 
Methods 
The PELICAN study was a prospective observational study, undertaken between 
January 2011 and February 2012 in seven consultant-led maternity units in the United 
Kingdom and Ireland. The role of placental growth factor (PlGF) in determining need 
for delivery within 14 days of sampling for preeclampsia in this study has previously 
been reported(7) and this was a planned further analysis.   
 
Participants 
Study eligibility required the presence of signs or symptoms of suspected preeclampsia 
in women presenting between 20+0 and 36+6 weeks’ gestation with a singleton or twin 
pregnancy and aged ≥16 years; women with confirmed preeclampsia at enrolment 
were excluded. Written informed consent was obtained and baseline demographic and 
pregnancy-specific information were entered onto the study database. Blood was 
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drawn into ethylenediamine tetra-acetic acid at study enrolment and samples spun at 
3000 rpm for 10 minutes. Plasma was extracted and stored at -80oC until analysis. 
Management of the women in the study followed usual care pathways for women with 
suspected pre-eclampsia, as advised in the National Institute for Health and Care 
Excellence Hypertension in Pregnancy guidelines,(8) with ultrasound assessment being 
undertaken as clinically indicated. 
 
Ultrasound assessments were undertaken by trained ultrasonographers at each study 
site as clinically indicated, using a variety of machined and following local protocols for 
measurement of fetal biometry, amniotic fluid index and umbilical artery Doppler flow 
velocity waveforms (as occurred in clinical practice at the time of the study). Quality 
control was undertaken through local procedures rather than by the research team 
centrally. Estimated fetal weight was calculated at each site using the Hadlock 
formula.(9) Additional parameters, including uterine, middle cerebral artery and 
ductus venosus Doppler studies were not universally reported and therefore could not 
be compared to biomarker performance. As study sites were reporting abnormal 
ultrasound assessment using a variety of parameters (including AC and EFW <10th, 
<5th, <3rd centiles), the most commonly reported parameters of AC or EFW <10th 
centile was chosen to enable comparison across sites. The presence of an abdominal 
circumference (AC) or estimated fetal weight (EFW) < 10th centile, oligohydramnios 
(amniotic fluid index < 5th centile or absent/ reversed end diastolic flow were recorded 
by study midwives.  
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Final diagnoses for maternal hypertensive disorders of pregnancy were assigned, 
following agreement by an adjudication panel of experts, using definitions from the 
American College of Obstetricians and Gynaecologists practice bulletin(10). SGA was 
defined as birthweight <3rd (SGA-3) customised centile (with birthweight <10th 
customised centile (SGA-10) as a secondary outcome), calculated using the Gestation 
Related Optimal Weight (GROW) method by freely available software(11). All 
diagnoses were assigned without knowledge of any biomarker values.  
 
The pre-specified first part of the biomarker analysis presented here relates to two 
groups of women in pre-defined gestational age strata enrolled with singleton 
pregnancies and suspected preterm preeclampsia: Group 1 at 20+0 to 34+6 weeks’ 
gestation and Group 2 at 35+0 to 36+6 weeks’ gestation. For comparison against 
ultrasound parameters, the second part of the analysis was restricted to women with 
an ultrasound performed within 14 days of blood sampling at enrolment. The principal 
pre-specified outcome for both analyses was delivery of an SGA infant (defined as 
birthweight < 3rd customised birthweight centile)(3). The pre-specified secondary 
outcome measures were birthweight less than the 10th customised centile and adverse 
perinatal outcome. Adverse perinatal outcome was pre-defined as presence of any of 
the following complications: antepartum/ intrapartum fetal or neonatal death, 
neonatal unit admission for >48 hrs at term, intraventricular haemorrhage, 
periventricular leucomalacia, seizure, retinopathy of prematurity, respiratory distress 
syndrome, bronchopulmonary dysplasia or necrotising enterocolitis. 
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Biomarker measurement 
The biomarkers were selected based on a priori knowledge of an association with 
preeclampsia, a biological role in placentation or a role in cellular mechanisms involved 
in the pathogenesis of preeclampsia e.g., angiogenesis, inflammation, coagulation. An 
initial panel of biomarkers was selected based on either a priori knowledge of an 
association with preeclampsia, a biological role in placentation or a role in cellular 
mechanisms involved in the pathogenesis of preeclampsia e.g., angiogenesis, 
inflammation, coagulation.  The full list of 47 biomarkers, measured with 57 assays 
(where potentially biologically important assays of different epitope specificity were 
available) was generated following a review of the literature, appraisal of selected 
bibliographies and consultation with medical experts (Table S1). 
 
Samples were labelled, and transported to the laboratory where they were spun at 
3000 rotations per minute for 10 minutes. Plasma samples were tested for Placental 
Growth Factor (PlGF) using the Triage PlGF Test by trained laboratory staff at the study 
site where the sample was taken (as previously published). The additional 56 
biomarker assays were analysed in a central laboratory facility (Alere, San Diego, CA) 
and full details of assay methods given in Text S2 and Table S3. All participants had 
delivered and pregnancy outcomes recorded before biomarker concentrations were 
analysed and revealed and all laboratory staff were masked to clinical outcomes. 
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Statistical analysis  
Standard distributional checks showed high levels of skewness for all 57 assays, which 
were consistent with underlying log normal distributions. Logged values of these 
biomarkers were therefore used. Before considering the pregnancy outcomes, 
statistical factor analysis of biomarker data was undertaken, reducing the 47 
biomarkers into a smaller number of highly correlated groups, solely on the basis of 
the correlations between the biomarkers. Factor summary scores were then calculated 
for all women. Consideration of scree plots and Eigen-values (> two) identified the 
most important factors for further analysis(12). These factors were rotated 
(orthogonal varimax method) so that each factor related strongly (correlation >0.6) to 
a small number of biomarkers only (factor analysis displayed in Table S4).  
 
The factor scores were entered into a multiple logistic regression model for prediction 
of subsequent SGA. Two factors (and their biomarkers) were identified for further 
investigation (Tables S5 and S6). Stepwise logistic regression was used to determine 
which biomarkers appeared to provide additional information beyond that derived 
from PlGF and prediction scores were extracted for the best combinations. A 
comparison of Receiver Operated Curves (ROC) areas of individual biomarkers and 
combinations was made to see if any of the additional information was both consistent 
and large enough to be clinically useful. Significance was assessed through use of a 
non-parametric test, which allowed for non-independence of observations on the 
same participant, with Bonferroni correction for multiple testing.  
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Some biomarkers, with high uniqueness scores, were not strongly associated with any 
factor. To investigate whether any of these biomarkers had prognostic power in 
addition to that provided by PlGF and biomarkers identified earlier, stepwise logistic 
regression was undertaken. 
 
The best performing biomarker was then assessed using standard test performance 
indices (sensitivity, specificity, predictive values and ROC areas) against currently 
utilised ultrasound parameters in the sub-group of women with an ultrasound scan 
within 14 days of blood sampling, for prediction of SGA and adverse perinatal 
outcome. A sensitivity analysis was conducted excluding those fetuses where the scan 
on the day of enrolment had abnormal findings (AC or EFW <10th centile, 
oligohydramnios or absent/ reversed end diastolic flow (n=20). 
 
Statistical analysis was carried out in the statistical package Stata (version 11.2), 
College Station Texas, USA. Formal significance was taken at p<0.05. The pre-specified 
sample size was calculated for accurate estimation of the sensitivity (within 10%) and 
specificity (within 6%) of a biomarker, assumed a sensitivity of 0.90, specificity 0.90, 
and 95% confidence intervals (CIs, two-tailed), for determining the primary endpoint; 
this required 62 patients with preeclampsia and 150 women not meeting the primary 
endpoint. The study is reported in accordance with Strengthening the Reporting of 
Observational Studies in Epidemiology guidelines (Text S7)(13).  
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The study was approved by East London Research Ethics Committee (ref. 
10/H0701/117). Participants gave informed consent and the study followed 
institutional guidelines. 
 
 
Results 
Between January 2011 and February 2012, 274 women presenting with suspected 
preeclampsia and a singleton pregnancy were enrolled between 20+0 and 34+6 weeks’ 
gestation (Group 1), and 123 women between 35 and 36+6 weeks’ gestation (Group 2) 
(figure 1).  
 
For Group 1, characteristics of these women at booking and enrolment are described 
in Table 1. Details of maternal and neonatal outcomes are shown in Table 2. Of 274 
women, 96 women (35.0%) delivered an SGA infant <3rd centile (SGA-3) (of whom 90% 
developed pre-eclampsia) and 130 women (47.4%) delivered an SGA infant <10th 
centile (of whom 81% developed pre-eclampsia). Adverse perinatal outcome was three 
times higher (39% vs. 13%) in cases complicated by SGA-3, compared to those with 
birthweights appropriate for gestational age. In six pregnancies a stillbirth occurred; in 
five of these women, the birthweight was <3rd centile. In all stillbirth cases the PlGF 
concentration was <5th centile at enrolment and predated ultrasound abnormalities by 
7 to 39 days and stillbirth by 10 to 53 days.  
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The predictive performance of the most promising biomarkers as depicted by ROC 
areas are shown in Table 3; (ROC areas for all 47 biomarkers measured are given in 
Table S8 and individual median biomarker concentrations in women sampled prior to 
35 weeks’ gestation are shown in Table S9). In isolation, PlGF had the best predictive 
performance, with an area under the ROC curve of 0.83 to detect SGA-3 when 
measured under 35 weeks’ gestation (sensitivity 89.7%, 81.7 to 94.9%; specificity 
58.7%, 51.1 to 66.0%; positive predictive value 53.8%, 45.7% to 61.7%; negative 
predictive value 91.3%, 84.6 to 95.8%). Combinations of the most promising 
biomarkers (Table 3) showed only minimal non-significant increases in ROC areas to 
predict SGA-3 (from 0.83 to 0.84) and SGA-10 (from 0.78 to 0.79). 
 
Of women enrolled prior to 35 weeks’ gestation, 129 had an ultrasound with all 
parameters recorded within 14 days of enrolment. The test performance of ultrasound 
parameters and PlGF (the best performing biomarker) for determining SGA-3 and SGA-
10 are shown in Table 4 and Table S10 respectively, with PlGF alone having a higher 
sensitivity (SGA-3 93% (CI 84% to 98%)) and negative predictive value (SGA-3 90% (CI 
76% to 97%)) than any other indicator in current clinical practice. Whilst addition of 
PlGF to currently used ultrasound parameters (abdominal circumference or estimated 
fetal weight <10th centile) increased the sensitivity to detect SGA-3 (68% to 97%), 
addition of ultrasound parameters to PlGF measurement did not markedly enhance 
sensitivity (93% to 97%). Adverse perinatal outcomes (excluding small for gestation age 
in this definition) occurred in 22% (60 of 274 infants). In predicting composite adverse 
perinatal outcome, PlGF had the highest sensitivity (90%) and negative predictive value 
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(90%) compared to all ultrasound measurements (n=129; Table 5). In a sensitivity 
analysis, performance of the ultrasound and PlGF variables was similar when those 
with an abnormal scan on the day of enrolment were excluded from the analysis 
(Tables S11 and S12).   
 
123 women were enrolled between 35+0 and 36+6 weeks’ gestation (group 2) and 
characteristics of these women at booking, enrolment and details of maternal and 
neonatal outcomes are described in Tables S13 and S14. ROC areas for all 47 
biomarkers measured between 35+0 and 36+6 weeks’ gestation are given in Table S13. 
When measured in isolation, PlGF had a ROC area of 0.69 for predicting SGA-3 and 
0.74 for SGA-10; addition of CPA-4 raised this to 0.77 for SGA-3 and 0.81 for SGA-10 
(Table S16). Addition of other biomarkers yielded little benefit. In this group, PlGF had 
higher sensitivity than all other currently used ultrasound indicators in predicting SGA 
infants (Tables S17 and S18) and adverse perinatal outcomes (Table S19).  
 
 
Discussion 
Our study has demonstrated that PlGF measurement has high sensitivity and negative 
predictive value in the determination of subsequent delivery of an SGA infant, and in 
prediction of adverse perinatal outcome, in women presenting with suspected preterm 
preeclampsia. We evaluated SGA <3rd birthweight centile to identify a fetus more 
likely to be growth restricted, rather than constitutionally small. Our study would 
suggest that PlGF measurement has a potential role alongside ultrasound assessment 
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in surveillance of high-risk women with suspected preeclampsia. This is particularly 
pertinent in healthcare settings where women with suspected pre-eclampsia do not 
routinely have ultrasound performed at presentation, where integration of PlGF with 
current ultrasound parameters may increase detection rates for SGA. Ultrasound has 
an essential role in the detection of falling growth velocity, oligohydramnios or 
abnormal umbilical artery Doppler waveforms, which will continue to be used to 
stratify surveillance and time delivery appropriately. The use of PlGF for prediction of 
SGA relates to this high-risk group of women with suspected preeclampsia and cannot 
be generalised to low-risk healthy pregnant women(14). 
 
Of 46 additional biomarker assays evaluated in isolation or combination with PlGF, 
there was added minimal incremental value to the predictive performance of PlGF 
alone and these are unlikely to be of utility in the clinical setting. It is possible that 
serial PlGF concentrations, with measurements closer to outcome, may further 
improve predictive ability while other biomarkers may only become significant closer 
to outcome. Placental pathology would have been a useful additional tool in assessing 
for fetal growth restriction but was not available in this study. 
 
A possible source of intervention bias is that ultrasound results were revealed to 
clinicians whilst biomarker results were not. At the time of the study in the UK, it was 
not common practice to deliver for falling growth velocity alone (i.e. pre-empting 
delivery of an SGA infant) unless the EFW fell below the <10th centile. Adverse 
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perinatal outcome (excluding SGA) was chosen as a secondary outcome to evaluate 
performance of the variables on this additional clinically meaningful endpoint. 
 
This study enrolled women who presented for obstetric assessment with a broad 
range of symptoms and signs of suspected preeclampsia, including those with 
underlying maternal disease. This is more informative than evaluating the tests against 
normal healthy pregnant women (as in a case-control study) as it is likely to more 
closely reflect test performance in the usual clinical setting. The multicentre nature of 
the study incorporating women of geographic and ethnic diversity adds to the 
generalisability of the results. Further strengths of the study include all final clinical 
diagnoses being adjudicated by a panel of medical experts and all clinical and 
laboratory staff being masked to biomarker results until study completion.  
 
It is a feature of our study that the assessments (including ultrasound examination) 
were performed within a local healthcare setting without referral, ultrasound or 
management protocols being dictated centrally by the research team. It is a strength 
that this pragmatic approach makes it likely that the prognostic variables would have 
comparable performance when translated beyond the research study, with the 
findings directly generalisable to similar healthcare settings. However, it is a potential 
limitation that such an approach does not reflect assessment of ultrasound as 
undertaken in some healthcare systems (e.g. by a maternal-fetal medicine 
subspecialist).   
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The findings of this study relate to similar healthcare settings where same-day 
ultrasound assessment is not routinely undertaken for women presenting with 
suspected pre-eclampsia, due to national guideline recommendations or lack of 
availability of trained ultrasonographers. In settings where all women with suspected 
pre-eclampsia undergo same-day ultrasound assessment by a maternal-fetal medicine 
subspecialist, performance of ultrasound may be different. As we included scans 
performed within 14 days after blood sampling, ultrasound may have been undertaken 
closer to the clinical endpoint (and would therefore not have been expected to bias 
against ultrasound test performance).   
 
We are not aware of any study that has compared such a wide panel of 47 biomarkers 
for prediction of subsequent SGA in women with suspected pre-eclampsia. Reports on 
the capability of PlGF to predict SGA have been conflicting. Initial small case-control 
studies in the first and second trimesters for prediction of SGA found no significant 
relationship(15-17) but subsequent larger case-control studies(18-20) and several 
prospective cohorts measuring PlGF in the second(21) and first trimester(22) have 
reported an association between low PlGF concentrations and subsequent SGA. The 
few small (n=21 or fewer), mainly case control studies where measurement has been 
undertaken in the third trimester (including at time of delivery) generally concur with 
our findings of low PlGF concentrations in women with subsequent SGA infants(23-26), 
particularly those with significant underlying placental pathology,(27) As impaired 
placental function underpins a substantial proportion of cases of SGA (and pre-
eclampsia)(28), an angiogenic placental factor such as PlGF has biological plausibility 
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for prediction. A recent systematic review of 53 studies (principally of first and second 
trimester prediction, and with no studies of PlGF in a similar cohort to this study) 
investigated the value of biomarkers in the prediction of fetal growth restriction in 
singleton pregnancies and concluded that PlGF emerged as the most promising of the 
37 biomarkers reported(6). The finding that PlGF measurements also predicted 
adverse perinatal outcome is supported by two other studies(29, 30) but the first 
evaluated PlGF measurements in the first trimester and the second reported a 
combined maternal and perinatal adverse outcome.  
 
SGA has the highest population-attributable risk value (23%) for stillbirth of all 
pregnancy-specific disorders(31). In this study cohort five of six cases complicated by 
stillbirth delivered an infant with a birthweight <3rd centile. In a setting where 
ultrasound is not routinely performed on all women with suspected pre-eclampsia, 
PlGF measurement might facilitate earlier and more accurate detection of SGA 
associated with perinatal mortality, allowing appropriate surveillance for those at 
highest risk with the aim of improving outcome. Such a strategy could allow 
appropriate targeting of resources to at risk pregnancies with subsequent 
improvements in maternal and fetal outcome.   
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Table 1 Characteristics of participants at booking and enrolment (grouped by 
subsequent infant birthweight) under 35 weeks’ gestation.  Values given are median 
(quartiles) or n (%) as appropriate 
Characteristics Women with SGA 
infant <3rd centile 
(n= 96) 
Women with SGA 
infant <10th centile 
(n=130) 
Women with infant 
≥ 10th centile  
(n=144) 
At booking:    
Age (years) 31.9 
(27.2 - 36.2)
31.9 
(27.4 - 36.4)
31.7 
(26.3 - 35.6)
BMI (kg/m2) 26.8 
(24.1 - 31.2) 
28.0 
(23.9 - 32.8) 
29.3 
(24.7 - 34.9) 
White ethnicity 63 (65.6) 87 (66.9) 92 (63.9) 
Highest systolic BP 
(mmHg) 
120
(110 - 130) 
121
(110 - 130) 
120 
(110 - 130) 
Highest diastolic BP 
(mmHg)  
74 
(65 - 81) 
74 
(65 - 81) 
75 
(68 - 82) 
Smoker at booking 17 (18.5) 24 (19.2) 29 (20.4) 
Quit smoking during 
pregnancy 
10 (10.9) 14 (11.2) 19 (13.4) 
Previous preeclampsia 
requiring delivery 
<34/40 
15 (15.8) 18 (14.0) 12 (8.6) 
Chronic hypertension 11 (11.5) 21 (16.2) 23 (16.0) 
At enrolment:   
Gestational age at 
sampling (weeks) 
31.0
(27.6 - 33.0) 
31.0
(27.6 - 33.1) 
31.1 
(28.0 - 33.6) 
New onset 
hypertension 
60 (63) 80 (62) 65 (45) 
Worsening of 
underlying 
hypertension 
16 (17) 24 (19) 32 (22) 
New onset of dipstick 
proteinuria 
58 (60) 79 (61) 71 (49) 
Highest systolic BP 
(mmHg) 
147 
(137 - 160) 
148 
(138 - 160) 
141 
(128 - 156) 
Highest diastolic BP 
(mmHg) 
94 
(83 - 100)
94 
(83 - 100)
90 
(80 - 100) 
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Table 2 Characteristics of delivery, maternal and neonatal outcome for women 
presenting before 35 weeks’ gestation. Values given are median (quartiles) or n (%) as 
appropriate 
Characteristics Women with SGA 
infant <3rd centile 
(n = 96) 
Women with SGA 
infant <10th centile 
(n = 130) 
Women with 
infant ≥ 10th 
centile 
(n = 144) 
Onset of labour  
Spontaneous 3 (3) 7 (5) 32 (23) 
Induced 29 (30) 42 (33) 64 (45) 
Pre-labour 
caesarean section 
64 (67) 80 (62) 46 (32) 
Mode of delivery  
Spontaneous vaginal 15 (16) 25 (20) 45 (31) 
Assisted vaginal  5 (5) 8 (6) 21 (15) 
Caesarean section 75 (79) 95 (74) 78 (54) 
Adverse maternal 
outcome* 
44 (46) 61 (47) 56 (39) 
Gestation at delivery 
(weeks) 
33.8  
(30.8 - 36.1)
34.4  
(31.4 - 37.3)
38.1  
(36 - 39.4) 
Fetal death 5 (5) 5 (4) 1 (1) 
Neonatal death 2 (2) 2 (2) 0 (0) 
Birth weight (g) 1537  
(1043 - 1910) 
1660  
(1200 - 2310) 
3128  
(2698 - 3545) 
SGA <10th 
birthweight centile 
96 (100) 130 (100) 0 (0) 
SGA <3rd birthweight 
centile  
96 (100) 96 (74) 0 (0) 
SGA <1st birthweight 
centile  
68 (71) 68 (53) 0 (0) 
Adverse perinatal 
outcome† 
37 (39) 41 (32) 19 (13) 
Maternal diagnosis    
No maternal disease 0 1 (0.8) 21 (15) 
Gestational 
hypertension 
1 (1) 1 (0.8) 25 (17) 
Chronic 
hypertension 
4 (4) 12 (9) 16 (11) 
Preeclampsia 86 (90) 106 (81) 59 (41) 
HELLP syndrome 1 (1) 1 (0.8) 1 (0.7) 
Other diagnosis 4 (4) 9 (7) 22 (16) 
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* Adverse maternal outcome defined as presence of any of the following 
complications: maternal death, eclampsia, stroke, cortical blindness or retinal 
detachment, hypertensive encephalopathy, systolic blood pressure ≥160mmHg, 
myocardial infarction, Intubation (other than for caesarean section), pulmonary 
oedema, platelets <50×10⁹/L (without transfusion), disseminated intravascular 
coagulation, thrombotic thrombocytopenic purpura/ haemolytic uraemic syndrome, 
hepatic dysfunction (alanine transaminase ≥70IU/L), hepatic haematoma or rupture, 
acute fatty liver of pregnancy, creatinine >150 μmol/L, renal dialysis, placental 
abruption, major postpartum haemorrhage, major infection. 
† Adverse perinatal outcome defined as presence of any of the following 
complications: antepartum/ intrapartum fetal or neonatal death, neonatal unit 
admission for >48 hrs at term, intraventricular haemorrhage, periventricular 
leucomalacia, seizure, retinopathy of prematurity, respiratory distress syndrome, 
bronchopulmonary dysplasia or necrotising enterocolitis.  
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Table 3 Test performance statistics for individual biomarkers and combinations 
(derived from logistic regression) to predict SGA <3rd centile and <10th centile in 
women presenting before 35 weeks’ gestation (ROC areas with 95% confidence 
intervals). P values are shown for comparison of a biomarker (or combination) 
performance vs. that for PlGF alone. [ ] low concentration of biomarker/ratio 
correlated to disease 
Biomarkers or combinations SGA <3rd centile SGA <10th centile P value (vs PlGF 
alone) 
Nephrin  0.63 (0.56 - 0.70) 0.62 (0.55 - 0.69) <0.001 
[CPA-4] 0.63 (0.57 - 0.70) 0.62 (0.55 - 0.68) <0.001 
sFlt-1 0.73 (0.67 - 0.79) 0.69 (0.63 - 0.76) <0.001 
Endoglin  0.74 (0.68 - 0.80) 0.73 (0.67 - 0.79) <0.001 
[PlGF] 0.83 (0.78 - 0.88) 0.79 (0.73 - 0.84) - 
Combinations  
[PlGF/s-Flt ratio] 0.80 (0.75 - 0.85) 0.77 (0.71 - 0.82) 0.004 
[PlGF/Endoglin ratio] 0.82 (0.77 - 0.86) 0.78 (0.73 - 0.83) 0.204 
[PlGF], [CPA-4] 0.83 (0.78 - 0.88) 0.79 (0.74 - 0.84) 0.560 
[PlGF], Nephrin 0.84 (0.79 - 0.88) 0.80 (0.74 - 0.85) 0.475 
[PlGF], Nephrin, [CPA-4] 0.84 (0.79 - 0.89) 0.80 (0.74 - 0.85) 0.390 
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Table 4 Test performance statistics (with 95% confidence intervals) for individual 
indicators and in combination to predict small for gestational age (SGA) <3rd 
customised birthweight centile in women presenting before 35 weeks’ gestation 
(n=129) 
Indicator Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
Positive 
predictive 
value % 
(95% CI) 
Negative 
predictive 
value % 
(95% CI) 
Positive 
likelihood 
ratio 
Negative 
likelihood 
ratio 
AC or EFW <10th 
cenƟle ‡ 
71.2 
(57.9 - 82.2) 
92.5 
(83.4 - 97.5) 
89.4 
(76.9 - 96.5) 
78.5 
(67.8 - 86.9) 
9.5 
(4.0 - 22.5) 
0.31 
(0.21 -0.47) 
Oligohydramnios 
§ 
18.6 
(9.7 - 30.9) 
98.5 
(92.0 – 100.0) 
91.7 
(61.5 - 99.8) 
57.9 
(48.3 - 67.1) 
12.5 
(1.7 - 3.9) 
0.83 
(0.73 - 0.94) 
AREDF || 20.3 
(11.0 - 32.8) 
98.5 
(92.0 – 100.0) 
92.3 
(64.0 - 99.8) 
58.4 
(48.8 - 67.6) 
13.6 
(1.8 - 101.7) 
0.81 
(0.71  - 0.92) 
PlGF <100 pg/ml 93.2 
(83.5 - 98.1) 
52.2 
(39.7 - 64.6) 
63.2 
(52.2 - 73.3) 
89.7 
(75.8 - 97.1) 
2.0 
(1.5  - 2.5) 
0.13 
(0.05 - 0.34) 
Combinations       
AC or EFW <10th 
centile or 
oligohydramnios 
or AREDF 
72.9 
(59.7 - 83.6) 
91.0 
(81.5 - 96.6) 
87.8 
(75.2 - 95.4) 
79.2 
(68.5 - 87.6) 
8.1 
(3.7 -17.7) 
0.30 
(0.19  -0.46) 
AC or EFW <10th 
centile or PlGF 
<100 pg/ml 
96.6 
(88.3 - 99.6) 
49.3 
(36.8 - 61.8) 
62.6 
(51.9 - 72.6) 
94.3 
(80.8 - 99.3) 
1.9 
(1.5 - 2.3) 
0.07 
(0.02 - 0.28) 
‡ Abdominal Circumference or EsƟmated Fetal Weight 
§ Oligohydramnios defined as amniotic fluid index <5th centile for gestational age 
|| Absent or Reversed End Diastolic Flow in umbilical artery Doppler flow velocity 
waveforms  
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Table 5 Test performance statistics (with 95% confidence intervals) for individual 
indicators and in combination to predict adverse perinatal outcome in women 
presenting before 35 weeks’ gestation (n=129) 
Indicator Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
Positive 
predictive 
value % 
(95% CI) 
Negative 
predictive 
value % 
(95% CI) 
Positive 
likelihood 
ratio 
Negative 
likelihood 
ratio 
AC or EFW <10th 
cenƟle ‡ 
48.7 
(32.4 - 65.2) 
67.8
(56.9 - 77.4) 
40.4
(26.4 - 55.7) 
74.7
(63.6 - 83.8) 
1.5 
(1.0 - 2.4) 
0.76
(0.54 - 1.06) 
Oligohydramnios §  12.8 
(4.3 - 27.4) 
92.0
(84.1 - 96.7) 
41.7
(15.2 - 72.3) 
70.2
(60.9 - 78.4) 
1.6 
(0.5 - 4.7) 
0.95
(0.83 - 1.09) 
AREDF || 12.8 
(4.3 - 27.4) 
90.8
(82.7 - 95.9) 
38.5
(13.9 - 68.4) 
69.9
(60.6 -78.2) 
1.4 
(0.5 - 4.0) 
0.96
(0.84 - 1.10) 
PlGF <100 pg/ml 89.7 
(75.8 - 97.1) 
40.2
(29.9 - 51.3) 
40.2
(29.9 - 51.3) 
89.7
(75.8 - 97.1) 
1.5 
(1.2 -1.8) 
0.25
(0.10 - 0.67) 
Combinations   
AC or EFW <10th 
centile or 
oligohydramnios 
or  AREDF 
53.8 
(37.2 - 69.9) 
67.8 
(56.9 - 77.4) 
42.9 
(28.8 - 57.8) 
76.6 
(65.6 - 85.5) 
1.7 
(1.1 - 2.6) 
0.68 
(0.47 - 0.98) 
AC or EFW <10th 
centile or PlGF 
<100 pg/ml 
92.3 
(79.1 -98.4) 
36.8
(26.7 - 47.8) 
39.6
(29.5 - 50.4) 
91.4
(76.9 - 98.2) 
1.5 
(1.2- 1.8) 
0.21
(0.07 - 0.64) 
‡ Abdominal Circumference or EsƟmated Fetal Weight 
§ Oligohydramnios defined as amniotic fluid index <5th centile for gestational age 
|| Absent or Reversed End Diastolic Flow in umbilical artery Doppler  
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Figure 1: Participant flow diagram 
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